Status:
COMPLETED
Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis
Eligibility:
All Genders
Brief Summary
The purpose of this survey is to evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.
Detailed Description
Bixalomer is administered at initial oral dosage of 500 mg three times a day just before a meal. The dosage can be adjusted based on symptoms and serum phosphorus level.
Eligibility Criteria
Inclusion
- Chronic renal failure patients with hyperphosphataemia receiving hemodialysis
Exclusion
Key Trial Info
Start Date :
January 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
1078 Patients enrolled
Trial Details
Trial ID
NCT01901107
Start Date
January 1 2013
End Date
December 1 2016
Last Update
January 27 2017
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Chūbu, Chubu, Japan
2
Chugoku, Chugoku, Japan
3
Hokkaido, Hokkaido, Japan
4
Kantou, Kantou, Japan